Researchers have developed a new approach that uses microRNA in combination with chemotherapy to help treat glioblastoma brain cancer. In preclinical models, the approach increases survival of the deadly brain cancer five fold.
Researchers report our gender can determine longevity and response to treatment for glioblastoma brain cancer. The study reports male survival is determined by genes that control cell division, where as female survival is often determine by genes that regulate the ability of cancer cells to migrate to different brain areas.
A new study reveals distinct molecular differences in signatures of glioblastoma brain cancer between men and women. Researchers report current treatments for the brain cancer are more effective in women than in men. The findings could help to tailor treatments aimed at the different sexes and improve survival.
Researchers detail the use of a drug that may help block the way glioblastoma brain cancer cells respond to fluid flow. The finding could lead to stopping glioblastoma from spreading.
A new study reports a genetically modified poliovirus therapy has been shown to improve long term survival rates in recurrent glioblastoma brain cancer patients. Researchers say the therapy had a three year survival rate for 21 percent of participants in a phase 1 clinical trial, compared to just 4% of patients who received more standard treatments.
Researchers at MIT have developed a new drug delivering nanoparticle that is able to cross the blood-brain barrier. The nanoparticles carry two different drugs that can help shrink tumors and prevent them from growing back.
Researchers use gene editing to generate aggressive glioblastoma multiforme brain tumors in the lab. The model, researchers say, could be used to track the progression of tumors and develop personalized therapies for patients.
Researchers report the addition of an FDA approved chemotherapy drug called hydroxyyurea to temozolomide helps to increase survival rates in animal models of glioblastoma.